Hepatocyte Lot No. | Parameters | RIS | R3 | Cmax/EC50 | AUC/F2 | |||
---|---|---|---|---|---|---|---|---|
Cmax-t | Cmax-u | Cmax-t | Cmax-u | Cmax-t | Cmax-u | |||
mRNA Data | ||||||||
Lot 295 | Cut-off valuea | 0.74 | 0.017 | 0.57 | 0.98 | 0.94 | 0.0088 | 6.2 |
95% CI | 0.54 | 0.013 | 0.20 | 0.029 | 0.079 | 0.00084 | 7.0 | |
R2 | 0.91 | 0.97 | 0.91 | 0.98 | 0.97 | 0.995 | 0.94 | |
Lot 312 | Cut-off valuea | 1.32 | 0.019 | 0.44 | 0.98 | 0.23 | 0.0056 | 12 |
95% CI | 0.28 | 0.0093 | 0.062 | 0.037 | 0.46 | 0.0028 | 3.4 | |
R2 | 0.97 | 0.99 | 0.97 | 0.98 | 0.84 | 0.99 | 0.97 | |
Lot 318 | Cut-off valuea | 0.62 | 0.011 | 0.62 | 0.99 | 0.33 | 0.0038 | 2.3 |
95% CI | 0.35 | 0.011 | 0.18 | 0.014 | 0.21 | 0.0021 | 2.6 | |
R2 | 0.96 | 0.96 | 0.97 | 0.97 | 0.97 | 0.97 | 0.95 | |
Activity Data | ||||||||
Lot 295 | Cut-off valuea | 0.60 | 0.017 | 0.63 | 0.98 | 0.62 | 0.0069 | 8.8 |
95% CI | 0.63 | 0.011 | 0.28 | 0.026 | 0.43 | 0.0034 | 5.4 | |
R2 | 0.87 | 0.97 | 0.87 | 0.98 | 0.88 | 0.98 | 0.98 | |
Lot 312 | Cut-off valuea | 0.84 | 0.013 | 0.56 | 0.99 | 0.58 | 0.005 | 4.4 |
95% CI | 0.37 | 0.0069 | 0.13 | 0.023 | 0.15 | 0.0025 | 2.7 | |
R2 | 0.93 | 0.98 | 0.93 | 0.98 | 0.97 | 0.99 | 0.97 | |
Lot 318 | Cut-off valuea | 0.57 | 0.0078 | 0.65 | 0.995 | 0.53 | 0.0052 | 1.0 |
95% CI | 0.18 | 0.0039 | 0.084 | 0.020 | 0.34 | 0.0025 | 3.2 | |
R2 | 0.97 | 0.99 | 0.97 | 0.98 | 0.96 | 0.99 | 0.78 |
CI, confidence interval.
↵a Values were either over- or underpredicted on the basis of the 0.9 cut-off value provided in the 2012 FDA draft guidance.